Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
Earnings Data
Report Date
Mar 02, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-3.89Last Year’s EPS
4.5Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlights significant achievements, including the transformative sale of FibroGen China, progress in prostate cancer treatment, and successful regulatory engagement for roxadustat. However, these are balanced by the low revenue and net loss figures, along with financial concerns regarding upcoming trials.Company Guidance
Transformative Sale of FibroGen China
FibroGen completed the sale of FibroGen China to AstraZeneca for approximately $220 million, providing efficient access to cash and extending the cash runway into 2028.
Progress in Prostate Cancer Treatment
Initiated Phase II monotherapy trial for FG-3246 in metastatic castration-resistant prostate cancer. Phase I results showed median radiographic progression-free survival of 8.7 months and PSA reductions greater than 50% in 36% of patients.
Regulatory Path for Roxadustat
Successful Type C meeting with the FDA for roxadustat, with plans to submit Phase III trial protocol for anemia treatment in lower-risk myelodysplastic syndromes by the end of the year.
Significant Cost Reduction
Total operating costs and expenses for Q3 2025 were reduced by 86% year-over-year to $6.5 million from $47.8 million in Q3 2024.
FGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 10, 2025 | $11.00 | $9.94 | -9.64% |
Aug 11, 2025 | $8.37 | $9.25 | +10.51% |
May 12, 2025 | $7.64 | $7.48 | -2.09% |
Mar 17, 2025 | $11.12 | $8.70 | -21.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does FibroGen (FGEN) report earnings?
FibroGen (FGEN) is schdueled to report earning on Mar 02, 2026, After Close (Confirmed).
What is FibroGen (FGEN) earnings time?
FibroGen (FGEN) earnings time is at Mar 02, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FGEN EPS forecast?
FGEN EPS forecast for the fiscal quarter 2025 (Q4) is -3.89.